FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
10 letters match. Newest first.
-
DrugsSCA Pharmaceuticals, LLC
SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.
High risk -
DevicesAbbott Diabetes Care, Inc.
FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.
High risk -
DevicesOnkos Surgical, Inc.
FDA warns Onkos Surgical over ELEOS implant system cleaning, corrective-action, risk, sampling, and removal-reporting failures.
High risk -
DrugsHealwell Homeo Private Limited
FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.
High risk -
DevicesMicrospecialties, LLC
FDA warned Microspecialties, a Connecticut contract device maker, after it shipped unsterilized eye-surgery injection kits labeled sterile.
High risk -
DrugsZydus Lifesciences Limited
FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.
High risk -
DrugsCentral Admixture Pharmacy Services, Inc.
FDA warned Central Admixture Pharmacy Services' Allentown outsourcing facility over sterile drug contamination and CGMP failures.
High risk -
DevicesFuture Diagnostics Solutions B.V.
FDA cites Future Diagnostics over quality-system and reporting failures for STAT IntraOperative Intact PTH immunoassay kits.
High risk -
DrugsHigley Industries, Inc.
FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.
High risk -
DrugsCetylite Industries, Inc.
FDA warned Cetylite Industries over CGMP violations at its Pennsauken, NJ facility, including unvalidated testing and inadequate OOS investigations for topical anesthetics.
High risk